# Ipamorelin Dosage in the Research: Doses Studied, Routes, and Half-Life

> Ipamorelin dosage as it appears in the literature: the doses, routes, and ~2 h human half-life actually studied. Research context only — no human dosing recommendation.

The doses, routes, and pharmacokinetics on record — reported third-person from the literature, never as a protocol to follow.

## The short version

This page describes the ipamorelin dosage figures that appear in published studies — what researchers gave, to which species, by which route. It is not a how-to. Most human numbers come from two studies: a pharmacology study using IV infusions of 4.21–140.45 nmol/kg [2], and a Phase 2 trial using 0.03 mg/kg IV twice daily for up to a week [3]. Animal studies used micrograms-per-day under the skin for bone work [4] and milligrams-per-kilogram for the 2024 ferret study [5]. The human half-life is about two hours [2]. Community 'stack' regimens with CJC-1295 have no peer-reviewed human dosing basis and are described here only as anecdotal, never recommended.

## Doses and routes on record

Across the literature, ipamorelin has been administered as follows. In the human pharmacokinetic study, single IV infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg ran over 15 minutes each [2]. In the Phase 2 ileus trial, the dose was 0.03 mg/kg IV twice daily on postoperative days 1–7 or until discharge [3]. In the rat bone-growth study, subcutaneous ipamorelin was 18, 90, or 450 µg/day, divided three times daily for 15 days [4]. In the 2024 ferret cachexia study, the dose was 1–3 mg/kg intraperitoneal [5]. Routes studied include intravenous (human PK and clinical trials; rodent efficacy), subcutaneous (rodent bone and body-composition work, and the dominant route in community use), intranasal (rodent PK, ~20% bioavailability), and intraperitoneal (rodent and ferret models). Ipamorelin itself is not orally bioavailable; only engineered analogs achieved meaningful oral absorption (~10% in dogs) [9].

## Half-life and pharmacokinetics

Ipamorelin's terminal half-life is about 2 hours in healthy human volunteers given IV infusions, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse peaking roughly 40 minutes (0.67 h) after dosing [2]. The kinetics were dose-proportional across the tested range — doubling the dose roughly doubled exposure, with no saturation [2]. In rats, plasma clearance is roughly five-fold lower than GHRP-6. These are the measured pharmacokinetics, not a schedule; they describe how the molecule behaves, not how anyone should use it.

## How much cjc-1295 ipamorelin should i take

How much cjc-1295 ipamorelin should i take is a question with no evidence-based answer, and this site does not provide a dose. There is no peer-reviewed human dosing protocol for ipamorelin alone or for the CJC-1295 combination; the only human ipamorelin doses on record are the IV research figures above [2][3], not subcutaneous self-administration regimens. The popular stack is supported by separate single-agent pharmacology, not by any human trial of the combination for any outcome [14]. Community subcutaneous protocols circulate widely, but they have no controlled-trial basis and are described here only as anecdotal, never as a recommendation.

## How to reconstitute cjc-1295 ipamorelin 5mg

How to reconstitute cjc-1295 ipamorelin 5mg is a peptide-handling question rather than a dosing one, and the literature speaks only in general terms. Ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction, and the human pharmacokinetics on record were measured for IV administration, not reconstituted subcutaneous mixtures [2].

---

A documentation-first desk that reads the newest ipamorelin studies first and carries every figure back to its PubMed source — no clinic behind the name, no medical advice, and nothing dosed, prescribed, or sold.